Kowa Presents Promising Non-Clinical Data for K-679 Unimicelle Conjugate

Kowa Company Ltd., headquartered in Nagoya, Japan, announced details about their novel compound, K-679. This innovative antibody drug-loaded unimicelle conjugate (ADUC) utilizes Kowa's proprietary micelle technology and has shown promising results in targeting EGFR-expressing solid tumors. The company will present these findings at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego.

K-679 boasts significant advantages such as tumor-selective pharmacokinetics and extensive intratumoral distribution. Its design involves combining an anti-EGFR antibody with a high drug loading of DM1 molecules, aiming for superior efficiency compared to conventional ADCs. Non-clinical studies have indicated notable anti-tumor activity, particularly in colorectal patient-derived xenograft models.

The AACR presentation, given by Hideo Yoshida, will provide a deeper look at K-679's selective intratumoral actions and its distinct performance compared to benchmark ADCs.